Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Atkinson

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Journal of Child and Adolescent Psychopharmacology|October 25, 2022
26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)Sarah Atkinson, Mary Bachinsky, Yaron Raiter, et al.
Forensic Science International|January 23, 2016
Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incenseKaren Blakey, Sue Boyd, Sarah Atkinson, et al.
Journal of Child and Adolescent Psychopharmacology|April 8, 2022
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication StudyRobert L Findling, Sarah Atkinson, Mary Bachinsky, et al.
CNS Spectrums|November 14, 2018
Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension TrialsSarah Atkinson, Louise Thurman, Sara Ramaker, et al.
The International Journal of Neuropsychopharmacology|February 24, 2010
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled studyNizar El-Khalili, Mark Joyce, Sarah Atkinson, et al.
Journal of Child and Adolescent Psychopharmacology|November 30, 2017
Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive DisorderSarah Atkinson, Shannon Lubaczewski, Sara Ramaker, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 29, 2015
Participatory design of a preliminary safety checklist for general practicePaul Bowie, Julie Ferguson, Marion MacLeod, et al.
Oncology and Therapy|October 13, 2025
The Management of ER-Low, HER2-Negative Breast Cancer in the United Kingdom: A Survey of Current Clinical PracticeKa Chai Sit, Alison M Berner, Conor McCahill, et al.
Plos One|June 8, 2012
Diarrhoea complicating severe acute malnutrition in Kenyan children: a prospective descriptive study of risk factors and outcomeAlison Talbert, Nahashon Thuo, Japhet Karisa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersAoife M L Hunter, Sarah Atkinson, Elaine Murray, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Journal of Child and Adolescent Psychopharmacology|October 25, 2022
26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)Sarah Atkinson, Mary Bachinsky, Yaron Raiter, et al.
Forensic Science International|January 23, 2016
Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incenseKaren Blakey, Sue Boyd, Sarah Atkinson, et al.
Journal of Child and Adolescent Psychopharmacology|April 8, 2022
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication StudyRobert L Findling, Sarah Atkinson, Mary Bachinsky, et al.
CNS Spectrums|November 14, 2018
Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension TrialsSarah Atkinson, Louise Thurman, Sara Ramaker, et al.
The International Journal of Neuropsychopharmacology|February 24, 2010
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled studyNizar El-Khalili, Mark Joyce, Sarah Atkinson, et al.
Journal of Child and Adolescent Psychopharmacology|November 30, 2017
Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive DisorderSarah Atkinson, Shannon Lubaczewski, Sara Ramaker, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 29, 2015
Participatory design of a preliminary safety checklist for general practicePaul Bowie, Julie Ferguson, Marion MacLeod, et al.
Oncology and Therapy|October 13, 2025
The Management of ER-Low, HER2-Negative Breast Cancer in the United Kingdom: A Survey of Current Clinical PracticeKa Chai Sit, Alison M Berner, Conor McCahill, et al.
Plos One|June 8, 2012
Diarrhoea complicating severe acute malnutrition in Kenyan children: a prospective descriptive study of risk factors and outcomeAlison Talbert, Nahashon Thuo, Japhet Karisa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersAoife M L Hunter, Sarah Atkinson, Elaine Murray, et al.
Pageof 8